Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus-based immunosuppression to reduce hepatocellular carcinoma recurrence after liver transplantation
2007-003275-40Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of sirolimus in hepatocellular carcinoma (HCC) and liver transplant, sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoints: HCC recurrence and Prevention of rejection. Started Jul 2008; status: completed.
02
Drugs
sirolimus
03
Conditions
hepatocellular carcinoma (HCC)liver transplant
Beyond the preview
Go deeper on 2007-003275-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003275-40.